Perspective Therapeutics, Inc.
CATX
$1.94
$0.094.87%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -30.56% | 33.70% | -10.54% | 39.48% | 119.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -30.56% | 33.70% | -10.54% | 39.48% | 119.63% |
| Cost of Revenue | 93.82% | -- | -- | -- | 1,661.24% |
| Gross Profit | -94.75% | 33.70% | -10.54% | 39.48% | -4,732.37% |
| SG&A Expenses | 66.92% | 55.90% | 10.57% | -11.78% | 428.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 75.56% | 89.54% | 43.00% | 33.67% | 2,076.19% |
| Operating Income | -78.62% | -91.12% | -46.23% | -33.54% | -955.78% |
| Income Before Tax | -262.51% | -57.98% | -18.86% | -25.71% | -1,073.69% |
| Income Tax Expenses | -126.72% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -105.78% | -57.98% | -18.86% | -1,179.73% | -1,864.92% |
| Earnings from Discontinued Operations | 98.86% | -- | 73.52% | 68.55% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -62.79% | -46.02% | -5.38% | -3,211.05% | -655.28% |
| EBIT | -78.62% | -91.12% | -46.23% | -33.54% | -955.78% |
| EBITDA | -252.44% | -89.66% | -44.25% | -32.59% | -1,005.89% |
| EPS Basic | 35.44% | 41.99% | 55.73% | -1,431.48% | -282.12% |
| Normalized Basic EPS | 38.21% | 37.24% | 50.31% | 41.79% | -759.60% |
| EPS Diluted | -29.56% | 41.99% | 55.73% | -1,431.48% | -282.12% |
| Normalized Diluted EPS | 38.21% | 37.24% | 50.31% | 41.79% | -759.60% |
| Average Basic Shares Outstanding | 152.15% | 151.75% | 138.04% | 116.59% | 97.70% |
| Average Diluted Shares Outstanding | 152.15% | 151.75% | 138.04% | 116.59% | 97.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |